Background Trastuzumab targets the extracellular domain of the HER2 protein. Adding
trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces …

Background Increasing the dose intensity of cytotoxic therapy by shortening the intervals
between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose …

Purpose Previous preclinical and clinical data suggest that the immune system influences
prognosis and response to chemotherapy (CT); however, clinical relevance has yet to be …

The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in this …

Background Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared
with tamoxifen, in postmenopausal women with hormone-receptor–positive breast cancer. …

Background Suppression of ovarian estrogen production reduces the recurrence of
hormone-receptor–positive early breast cancer in premenopausal women, but its value when added …

Author links open overlay panel F. Cardoso a, A. Costa bc, L. Norton d, E. Senkus e, M. Aapro
f, F. André g, CH Barrios h, J. Bergh i, L. Biganzoli j, KL Blackwell k, MJ Cardoso l, T. Cufer …

Purpose The aim of the current study was to conduct a pooled analysis of studies that have
investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple …

Background In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and
Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly …

Background Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of
gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown …